From: Overexpression of HSPA2 is correlated with poor prognosis in esophageal squamous cell carcinoma
Features | Overall survival | Disease-free survival | ||
---|---|---|---|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |
Age (≤60/>60 years) | 0.713 (0.456 to 1.116) | 0.139 | 0.745 (0.493 to 1.125) | 0.162 |
Gender (female/male) | 0.915 (0.553 to 1.513) | 0.728 | 0.975 (0.624 to 1.525) | 0.913 |
Drinking (yes/no) | 1.043 (0.670 to 1.622) | 0.853 | 1.017 (0.681 to 1.518) | 0.935 |
Tumor site (upper + lower/middle) | 1.347 (0.797 to 2.277) | 0.266 | 1.216 (0.768 to 1.926) | 0.405 |
Grade (G2 + G3 + G4/G1) | 1.137 (0.739 to 1.749) | 0.559 | 1.070 (0.723 to 1.584) | 0.735 |
Primary tumor (T3 + T4/T1 + T2) | 2.157 (1.380 to 3.372) | 0.001a | 1.872 (1.256 to 2.791) | 0.002a |
TNM stage (III/I + II) | 21.177 (11.057 to 40.561) | <0.001a | 15.085 (8.320 to 27.350) | <0.001a |
Lymph node metastases (−/+) | 0.572 (0.369 to 0.887) | 0.012a | 0.625 (0.418 to 0.935) | 0.022a |
HSPA2 expression (positive/negative) | 3.557 (1.827 to 6.922) | <0.001a | 2.901 (1.721 to 4.888) | <0.001a |